|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||60.74 - 67.80|
|52 Week Range||26.56 - 78.75|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2020 - Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.00|
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2020, and provided a review of recent accomplishments and anticipated upcoming milestones.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Sixth Street, a leading global investment firm.